Zota Health Care LImited (ZOTA) fundamentals
Zota Health Care LImited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ZOTA (ISIN INE358U01012). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Zota Health Care LImited does
Zota Health Care Limited is an India-based pharmaceutical company, which is engaged in the manufacturing and marketing of pharmaceutical products catering to domestic and international markets. It engages in manufacturing, marketing, and exporting a range of pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products. The Company’s business model comprises three vertical, namely Domestic, Exports, and Retail Pharmacy Chain. Its Domestic Marketing business vertical involves the direct distribution of generic drugs, OTC products, and other pharmaceutical products. Its product portfolio offers over 4,000 therapeutic product categories such as generics, OTC products, allopathic, ayurvedic, and others. Its Retail Pharmacy Chain business operates a chain of approximately 880 pharmacy stores under the brand Davaindia. It exports to over 30 countries. Its Domestic products include AZIVAR-100 DT Tab, AZIVAR-250 Tab, AZIVAR-500 Tab verticals, AZIVAR-CX Tab, among others.
Valuation and market data
| Last close | ₹1087.00 |
|---|---|
| Market capitalisation | ₹2,982 crore |
| Enterprise value | ₹3,090 crore |
| P/E (TTM) | 0.00 |
| Price to book | 13.13 |
| Price to sales (TTM) | 4.83 |
| Book value per share | ₹82.79 |
| Dividend yield | 9.20% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Aug 19 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹546 crore | ₹-80 crore | ₹-74 crore | 0.00 |
| Mar 2025 | ₹295 crore | ₹-58 crore | ₹-57 crore | -20.68 |
| Mar 2024 | ₹182 crore | ₹-16 crore | ₹-14 crore | -5.59 |
| Mar 2023 | ₹142 crore | ₹-5 crore | ₹-6 crore | -2.29 |
| Mar 2022 | ₹133 crore | ₹12 crore | ₹9 crore | 3.58 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 49.4% |
|---|---|
| Foreign institutions (FII) | 7.9% |
| Mutual funds | 0.4% |
| Other domestic institutions | 6.4% |
| Retail and others | 36.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.